2425 Sidney Street
9 articles with Complexa
Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease
Complexa Inc. today announced the completion of patient enrollment in the FIRSTx study, a Phase 2 clinical trial evaluating the safety and efficacy of the company’s lead candidate, CXA-10, to treat primary focal segmental glomerulosclerosis (FSGS).
Experienced industry leader to head Complexa’s clinical development programs
First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension
Complexa Inc. announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension.
First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis
FSGS is a rare and severe form of kidney disease that can lead to permanent kidney damage and even kidney failure.
Founder of Acerta Pharma to lead Complexa as it advances Phase 2 clinical development of lead compound CXA-10 in two orphan indications
Complexa Raises $62 Million In Series C Financing To Test CXA-10 In Two Orphan Disease Proof-Of-Concept Trials
Complexa Announces Successful Completion Of Four Phase 1 Studies Of CXA-10 And Planned Phase 2 Initiation In Multiple Orphan Indications During 2016